SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 331 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $282,927 | -6.2% | 2,334 | -11.4% | 0.17% | -3.9% |
| Q2 2023 | $301,760 | -10.2% | 2,635 | +8.1% | 0.18% | -3.2% |
| Q1 2023 | $335,892 | +8.2% | 2,437 | +1.8% | 0.18% | +14.2% |
| Q4 2022 | $310,344 | -23.2% | 2,395 | -34.4% | 0.16% | +0.6% |
| Q3 2022 | $404,000 | +49.6% | 3,653 | +1.6% | 0.16% | +61.0% |
| Q2 2022 | $270,000 | -20.4% | 3,596 | -17.2% | 0.10% | -34.2% |
| Q1 2022 | $339,000 | -13.3% | 4,345 | 0.0% | 0.15% | +2.7% |
| Q4 2021 | $391,000 | -20.4% | 4,345 | -18.2% | 0.15% | -31.5% |
| Q3 2021 | $491,000 | +8.9% | 5,311 | -8.4% | 0.22% | +16.8% |
| Q2 2021 | $451,000 | +64.0% | 5,798 | +57.3% | 0.18% | +59.5% |
| Q1 2021 | $275,000 | -55.1% | 3,686 | +2.7% | 0.12% | -54.3% |
| Q4 2020 | $612,000 | +18.4% | 3,590 | -2.4% | 0.25% | -6.3% |
| Q3 2020 | $517,000 | -4.3% | 3,679 | +9.2% | 0.27% | +5.9% |
| Q2 2020 | $540,000 | +23.9% | 3,369 | -24.4% | 0.26% | +43.0% |
| Q1 2020 | $436,000 | -30.1% | 4,457 | -7.8% | 0.18% | +75.5% |
| Q4 2019 | $624,000 | +43.1% | 4,833 | -16.6% | 0.10% | +15.9% |
| Q3 2019 | $436,000 | -57.6% | 5,794 | -14.4% | 0.09% | -59.4% |
| Q2 2019 | $1,029,000 | +89.5% | 6,770 | +36.1% | 0.22% | +133.3% |
| Q4 2018 | $543,000 | -57.6% | 4,976 | -37.2% | 0.09% | -29.5% |
| Q3 2018 | $1,280,000 | +31.0% | 7,925 | +7.2% | 0.13% | -84.7% |
| Q2 2018 | $977,000 | -19.7% | 7,391 | -55.0% | 0.86% | -18.1% |
| Q1 2018 | $1,216,000 | +22.1% | 16,409 | -8.3% | 1.06% | -15.6% |
| Q4 2017 | $996,000 | -29.7% | 17,897 | -42.7% | 1.25% | +554.5% |
| Q3 2017 | $1,417,000 | +34.6% | 31,233 | 0.0% | 0.19% | +21.7% |
| Q2 2017 | $1,053,000 | +3.0% | 31,233 | -9.6% | 0.16% | -13.7% |
| Q1 2017 | $1,022,000 | +19.4% | 34,536 | +10.6% | 0.18% | -28.9% |
| Q4 2016 | $856,000 | +7.7% | 31,215 | +141.1% | 0.26% | -33.3% |
| Q3 2016 | $795,000 | +221.9% | 12,949 | 0.0% | 0.38% | +109.8% |
| Q2 2016 | $247,000 | +87.1% | 12,949 | +91.3% | 0.18% | +0.5% |
| Q1 2016 | $132,000 | -52.5% | 6,770 | -6.0% | 0.18% | -76.1% |
| Q4 2015 | $278,000 | – | 7,203 | – | 0.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |